Every in-house attorney probably can name a couple of issues they have lost sleep over within the last few years. With more regulations in many industries and the enforcement landscape getting more treacherous, there are lots of reasons for restless nights. New data from a survey of in-house leaders at life sciences companies, conducted by ALM Legal Intelligence (an affiliate of Corporate Counsel) and sponsored by Foley Hoag, shows that one issue—the False Claims Act—stands above the rest as the biggest concern.
The data, which ALI gathered from general counsel and compliance counsel at U.S. biotechnology, medical device and health-care companies across the country, is outlined in a white paper, “Life Sciences Legal Forecast: 2014 Compliance Issues Keeping Executives Up at Night.” In addition to assessing the level of concern reported by in-house leaders about different legal and compliance issues, the white paper also looked at how these companies managed their FCA risk.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
